Abstract:Introduction: Pneumococcus is an important respiratory pathogen that is associated with high rates of death in newborn children and the elderly. Given the disadvantages of current polysaccharide-based vaccines, the most promising alternative for developing improved vaccines may be to use protein antigens with different roles in pneumococcus virulence. PspA and PhtD, highly immunogenic surface proteins expressed by almost all pneumococcal strains, are capable of eliciting protective immunity against lethal infections. Methods: In this study using immunoinformatics approaches, we constructed one fusion construct (called PAD) by fusing the immunodominant regions of PspA from families 1 & 2 (PA) to the immunodominant regions of PhtD (PD). The objective of this project was to test the immunogenicity of the fusion protein PAD and to compare its protective activity against S. pneumoniae infection with PA or PD alone and a combination of PA and PD. The prediction of physicochemical properties, antigenicity, allergenicity, toxicity, and 3D-structure of the constructs, as well as molecular docking with HLA receptor and immune simulation were performed using computational tools. Finally, mice were immunized and the serum levels of antibodies/cytokines and functionality of antibodies in vitro were evaluated after immunization. The mice survival rates and decrease of bacterial loads in the blood/spleen were examined following the challenge. Results: The computational analyses indicated the proposed constructs could be antigenic, non-allergenic, non-toxic, soluble and able to elicit robust immune responses. The results of actual animal experiments revealed the candidate vaccines could induce the mice to produce high levels of antibodies and cytokines. The complement-mediated bactericidal activity of antibodies was confirmed and the antibodies provided favorable survival in immunized mice after bacterial challenge. In general, the experimental results verified the immunoinformatics studies. Conclusion: For the first time this report presents novel peptide-based vaccine candidates consisting of immunodominant regions of PspA and PhtD antigens. The obtained findings confirmed that the fusion formulation could be relatively more efficient than the individual and combination formulations. The results propose that the fusion protein alone could be used as a serotype-independent pneumococcal vaccine or as an effective partner protein for a conjugate polysaccharide vaccine.

A Bacterial Vesicle-Based Pneumococcal Vaccine Against Influenza-Mediated Secondary Streptococcus Pneumoniae Pulmonary Infection.

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice

Broad Protective Immune Responses Elicited by Bacterium-Like Particle-Based Intranasal Pneumococcal Particle Vaccine Displaying PspA2 and PspA4 Fragments.

Protection Elicited by Nasal Immunization with Pneumococcal Surface Protein A (pspa) Adjuvanted with Bacterium-Like Particles Against Streptococcus Pneumoniae Infection in Mice

A Pneumococcal Vaccine Combination with Two Proteins Containing PspA Families 1 and 2 Can Potentially Protect Against a Wide Range of Streptococcus Pneumoniae Strains

Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection

Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

Pneumonic Plague Protection Induced by a Monophosphoryl Lipid A Decorated Yersinia Outer‐Membrane‐Vesicle Vaccine

Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection

Comparison Of Immunogenicity And Protection Of Two Pneumococcal Protein Vaccines Based On Psaa And Pspa

A Novel DNA Vaccine Expressing the Ag85A-HA2 Fusion Protein Provides Protection Against Influenza A Virus and Staphylococcus Aureus

Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV

An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae

Systemic and Mucosal Immune Responses Elicited by Intranasal Immunization with a Pneumococcal Bacterium-Like Particle-Based Vaccine Displaying Pneumolysin Mutant Plym2.

Memory Th17 cell-mediated protection against lethal secondary pneumococcal pneumonia following influenza infection

A new candidate epitope-based vaccine against PspA PhtD of Streptococcus pneumoniae: a computational experimental approach

Bacterium-like Particles from Corynebacterium pseudodiphtheriticum as Mucosal Adjuvant for the Development of Pneumococcal Vaccines

Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine

Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1

Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice

Remodeling Yersinia pseudotuberculosis to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague